Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNASDAQInformation TechnologyAerospace & DefenseSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ASTC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Gross profit improvement through cost management | Gross profit rose from $42,000 to $67,000 in the same period. | Broken | gross profit falls below $67,000 by 2026-Q3 | Gross profit: $-46,000 FY2026-Q4; GAAP. Published target: >= $67,000 gross profit by 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 25, 2026-46,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story, not a proven compounder, because the company is loss-making and recent performance is weak. The thesis is in a watch state: the signal has shifted from restrictive to cautious, but performance remains well below its industry cohort.
The valuation model describes ASTC as expensive versus peers, with a negative expectations gap, meaning current expectations look ahead of what the evidence supports. Pricing is tagged as justified, with low measured fragility, but model confidence is medium and the business remains loss-making.
Near term, erratic earnings surprises and weaker results than the industry make the next report an important check; the estimated miss probability is 47%. Over the multi-year view, management has named lunar resource development and a possible sale of 1st Detect as priorities, but neither has reported a direct financial contribution yet.
The favorable case depends partly on execution of the 1st Detect sale process and progress on lunar initiatives, which are both at an early stage. Near-term conditions could improve if rates ease or technology-sector pressure stabilizes, while materially slower economic growth could weigh on the business.
Over the next 1 to 3 years, ASTC’s thesis depends on turning new strategic plans into measurable business progress while addressing weak results and earnings uncertainty. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in ASTROTECH CORP's published investment case. The stated target is operating loss improves toward less negative than -$3.45 million by 2026-Q3. |
| Broken |
| operating loss worsens beyond -$3.45 million by 2026-Q3 |
Operating income: $-3.248M FY2026-Q4; GAAP. Published target: operating loss improves toward less negative than -$3.45 million by 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 25, 2026-3,248,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth from strategic partnerships | A primary condition in ASTROTECH CORP's published investment case. The stated target is >= $343,000 revenue by 2026-Q3. | Broken | revenue growth falls below $343,000 by 2026-Q3 | Revenue: $913,000 FY2026-Q4; GAAP. Published target: >= $343,000 revenue by 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 25, 2026913,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.